DOI · e01.org

Histamine H4 receptor is a potential target for COVID-19 treatment

Seyed Reza Mirmazloomi, Nazanin Gholinia, Amir Peymani · Electronic physician · 2020

  • DOI 10.19082/7776
  • Publisher Electronic Physician
  • Type article
  • Issued 2020

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Electronic physician · Electronic Physician · article · 2020

Abstract

Pulmonary fibrosis and cytokine storms are two major complications in COVID-19 patients that can decrease life quality after recovery and even cause death.Histamine H4 Receptor (H4R) antagonists prevent lung fibrosis and reduce TNF-α and IL-6 secretion in several immune-mediated diseases.T-helper cell 17 (TH17), which is an important inflammatory effector in COVID-19 pathogenesis, expresses H4Rs on its surface.The stimulation of these receptors results in IL-17 production and, subsequently, TNF-α and IL-6 secretion, tissue remodelling, and fibrosis.The compatibility of the clinical manifestations of COVID-19 with the H4R function pattern further supports this theory.According to the above content, Histamine 4 receptors could be a potential target for COVID-19 treatment.H4R antagonists should be evaluated in experimental in-vitro studies and randomized controlled trials in terms of their therapeutic and preventive effects in COVID-19 complications, severity progression, and mortality.

Open the resolved locator · 10.19082/7776

Metadata licence: OpenAlex metadata (CC0)